Theravance Biopharma Inc Stock News

Analyses from Randomized Controlled Trials Further Support the Target Engagement and Safety Profile of Ampreloxetine in Neurodegenerative Disease DUBLIN , April 7, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced new analyses from its previous Phase 3 program evaluating ampreloxetine, an investigational medicine for the tre...

DUBLIN , March 31, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a fireside chat at the Jones Healthcare and Technology Innovation Conference in Las Vegas on Wednesday, April 9 at 11:30 am PDT (2:30 pm EDT/6:30 PM GMT). Members of Theravance Biopharma senior management will also be hosting one-on-one meetings at the conference.

DUBLIN , March 27, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced new analyses of the initial Phase 3 program of ampreloxetine (Studies 169 and 170) supporting its selective and differentiated pharmacodynamic profile will be presented at the 77th Annual Meeting of the American Academy of Neurology (AAN) Meeting, taking pl...

Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q4 2024 Earnings Conference Call February 26, 2025 5:00 PM ET Company Participants Rick Winningham – Chief Executive Officer Rhonda Farnum – Chief Business Officer Aziz Sawaf – Chief Financial officer Aine Miller – Head-Development Conference Call Participants Douglas Tsao – H.C. Wainwright Julian Harrison – BTIG David Risinger – Leerink Partners Operat...

YUPELRI® (revefenacin) US net sales, recognized by Viatris, reached an all-time high of $66.7 million in Q4 2024 and $238.6 million in FY 2024, up 10% and 8%, respectively, compared with 2023 1 FY 2024 TRELEGY Net Sales, as reported by GSK, of $3.46 billion, up 26% compared with 2023 and triggering a $50 million milestone to Theravance Biopharma 2 , 3 CYPRESS study on track to enroll final pati...

DUBLIN , Feb. 20, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will present at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4 at 11:50 am EST (8:50 am PST/4:50 pm GMT) and will be hosting in-person meetings with the investment community at the conference. Webcast of the event may be accessed by visiting Theravance.com, under the Investors section, Events a...

DUBLIN, Ireland , Feb. 12, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its fourth quarter and full year 2024 financial results and provide a business update after market close on Wednesday, February 26, 2025. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm EST (2:00 pm PST/10:00 pm GMT) that day.

DUBLIN , Feb. 5, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12 at 12:00 pm EST (9:00 am PST/5:00 pm GMT).  Webcast of the event may be accessed by visiting Theravance.com, under the Investors section, Events and Presentations.